Target Audience: This activity is intended for health care professionals who are involved in the care of women. This may include physicians, general internists, gastroenterologists, obstetricians/gynecologists, nurse practitioners, physician assistants, practitioners in the field of psychiatry, and dieticians.
Instructions on How to Receive CME Credit: In order to receive CME credit for reviewing this presentation, participants must review the CME information (learning objectives, disclosures, etc.) and view the entire presentation. At the conclusion of the slide presentation, please click on the provided link and complete the self-assessment, evaluation, and CME credit attestation form.
Statement of Need: Irritable Bowel Syndrome (IBS) is the most commonly diagnosed digestive disorder in the United States, with prevalance estimated to be 10 to 15% (5 million individuals). Effective treatment of this requires a multifaceted approach, and includes medical, psychological and lifestyle therapy. This presentation is designed to provide information to clinicians on an integrated approach to treating irritable bowel syndrome by one of the country's leading authorities on Irritable Bowel Syndrome, Dr. Douglas Drossman.
Term of Offering: This webcast, with a release date of February 1, 2006, is valid for 1 year. Requests for credit must be received no later than January 31, 2007. Estimated time to complete is 1 hour 15 minutes (1.25 credits).
Copyright Information: Slides from the AGA Gastroenterology Teaching Program have been used as part of the content of this program. Permission has been granted by the American Gastroenterological Association to reproduce these slides.
Commercial Support Acknowledgment: This activity is supported by an unrestricted educational grant from Novartis Pharmaceuticals.
Disclaimer: The information provided in this case-based CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) when products of procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analysis, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
